Updates are available Correction dated 2024-10-01
Click to view Correction: https://doi.org/10.1007/s40121-024-01059-1
-
Authors
Marshall, Gary S. https://orcid.org/0000-0002-8731-6926
McCormick, Zachary L. https://orcid.org/0000-0003-4250-8745
Johns, Jeffery S. https://orcid.org/0009-0009-5751-2385
Verduzco-Gutierrez, Monica https://orcid.org/0000-0003-0964-5908
Herrera-Restrepo, Oscar https://orcid.org/0000-0001-8193-999X
Harrison, Lee H. https://orcid.org/0000-0002-3787-2705
-
Funding
Funding for this research was provided by:
GlaxoSmithKline Biologicals
- License Information
-
More Information
Article History
Received: 30 May 2024
Accepted: 26 July 2024
First Online: 30 August 2024
Change Date: 1 October 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40121-024-01059-1
Declarations
:
: Gary S. Marshall received grants/contracts (paid to institution) from GSK, Merck, Pfizer, Sanofi, and Seqirus; advisory board consulting fees and travel/meeting support from GSK, Merck, Moderna, Pfizer, Sanofi, and Seqirus. Zachary L. McCormick reported medical writing support for the present manuscript from GSK; study grants (paid to institution) from Avanos Medical, Relievant Medsystems, Boston Scientific, SPR Therapeutics, Spine Biopharma, Saol Therapeutics, and Stratus Medical; consulting fees from Avanos, Stryker, OrthoSon, and Saol Therapeutics; payment for expert testimony from law firms; data safety monitoring board or advisory board participation at FUSMobile; Board of Directors membership at International Pain and Spine Intervention Society, American Board of Pain Medicine, and Pacific Spine and Pain Society. Jeffery S. Johns reported participation on a GSK advisory board; and service as Vice Chair on the American Board of Physical Medicine and Rehabilitation. Monica Verduzco-Gutierrez reported grants from the Agency for Healthcare Research and Quality of US Department of Health and Human Services and Ipsen (paid to institution); honoraria for lectures/speakers bureau from Piramal, AbbVie, Ipsen, and Merz; payments for expert testimony (both to institution and author); consultancy with Revance; data safety monitoring board participation at Pacira and advisory board participation at GSK; board participation at the Association of Academic Physiatrists and RSVP clinic (unpaid). Oscar Herrera-Restrepo is a GSK employee and stockholder. Lee H. Harrison reported scientific advisory board participation at Sanofi, GSK, and Pfizer, and data safety monitoring board participation at Merck (all unpaid except reimbursement for any travel expenses).
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
